Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 20;12:645085. doi: 10.3389/fendo.2021.645085

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Müller, Robles, Zamora, Ebnet, Markl-Hahn, Martínez de la Escalera, Clapp, Bertsch and Triebel

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

ELISA of coated vasoinhibin and PRL with vasoinhibin-specific monoclonal antibodies. Four FDK-antibodies and seven HTS-antibodies were tested in a semi-quantitative indirect ELISA for their specificity to detect coated vasoinhibin in comparison to coated full-length PRL. The affinity of each antibody with vasoinhibin represented by its O.D. is plotted on the x-axis, and the affinity of each antibody with PRL by its O.D. on the y-axis, each antibody is indicated as a cross with mean and standard deviation, derived from triplicate measurements. The center point of each cross is the mean O.D. value of the triplicate measurement, and the lines show the range of the standard deviation. The green line represents the signal localization of the cross centers in case of equal affinity against vasoinhibin and PRL. The selected antibodies are shown in red. All tested antibodies are right of the green line toward the x-axis, which demonstrates a preference of vasoinhibin over PRL.